Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician
- PMID: 20091089
- DOI: 10.1007/s11239-009-0437-9
Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician
Abstract
The use of anticoagulant and antiplatelet therapy during the management of acute coronary syndromes (ACS) has been associated with improvements in short- and long-term clinical outcomes, regardless of whether patients are managed conservatively or with acute coronary revascularization. Translating the existing evidence for selection of the most appropriate antithrombotic strategy has been summarized in available guideline recommendations. Given the breadth of antithrombotic recommendations across existing U.S. and European guidelines, synthesis of these recommendations for practicing clinicians who treat patients with ACS are increasingly desired. Providing a summary of the similarities across guidelines while noting the areas where divergence exists becomes an important facet in translating optimal antithrombotic management in ACS for the treating clinician. This review highlights the important aspects of clinical practice guidelines that practicing physicians should consider when selecting antithrombotic therapies to reduce ischemic risk while minimizing hemorrhagic risk across all ACS subtypes.
Similar articles
-
Tailored antithrombotic therapy for acute coronary syndromes.Expert Rev Cardiovasc Ther. 2008 Aug;6(7):935-44. doi: 10.1586/14779072.6.7.935. Expert Rev Cardiovasc Ther. 2008. PMID: 18666844 Review.
-
Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.Pharmacotherapy. 2014 Jun;34(6):590-604. doi: 10.1002/phar.1375. Epub 2013 Dec 13. Pharmacotherapy. 2014. PMID: 24338703 Review.
-
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.J Interv Cardiol. 2008 Apr;21(2):107-17. doi: 10.1111/j.1540-8183.2007.00335.x. Epub 2008 Jan 30. J Interv Cardiol. 2008. PMID: 18248357 Review.
-
Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms?J Thromb Thrombolysis. 2010 Oct;30(3):332-9. doi: 10.1007/s11239-010-0487-z. J Thromb Thrombolysis. 2010. PMID: 20464453 Review.
-
Antiplatelet intervention in acute coronary syndrome.Am J Ther. 2009 Sep-Oct;16(5):e29-40. doi: 10.1097/MJT.0b013e31804c7238. Am J Ther. 2009. PMID: 19092648 Review.
Cited by
-
Cost effectiveness of anticoagulation in acute coronary syndromes.Pharmacoeconomics. 2012 Apr;30(4):303-21. doi: 10.2165/11589290-000000000-00000. Pharmacoeconomics. 2012. PMID: 22409291 Review.
-
Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.Clin Pharmacokinet. 2012 May 1;51(5):305-18. doi: 10.2165/11630960-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22489610 Review.
-
Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.J Thromb Thrombolysis. 2012 Jul;34(1):20-30. doi: 10.1007/s11239-012-0744-4. J Thromb Thrombolysis. 2012. PMID: 22562147 Review.
-
Ticagrelor: a review of its use in the management of acute coronary syndromes.Drugs. 2011 May 7;71(7):909-33. doi: 10.2165/11206850-000000000-00000. Drugs. 2011. PMID: 21568367 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical